EPID-01. GLIOBLASTOMA TREATMENT OF BEVACIZUMAB ERA IN KANSAI REGION, JAPAN

Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Mori, Kanji, Shofuda, Tomoko, Okita, Yoshiko, Arita, Hideyuki, Kinoshita, Manabu, Terakawa, Yuzo, Tsuyuguchi, Naohiro, Tomogane, Yusuke, Fukai, Junya, Ishibashi, Kenichi, Nishida, Namiko, Taki, Takuyu, Nonaka, Masahiro, Izumoto, Shuichi, Moriuchi, Shusuke, Nakajima, Yoshikazu, Hashimoto, Naoya, Kodama, Yoshinori, Hirose, Takanori, Kanemura, Yonehiro
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2017
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693178/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.279
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料